UK markets closed
  • NIKKEI 225

    29,222.77
    +353.86 (+1.23%)
     
  • HANG SENG

    19,922.45
    +91.93 (+0.46%)
     
  • CRUDE OIL

    87.44
    -0.67 (-0.76%)
     
  • GOLD FUTURES

    1,777.40
    +0.70 (+0.04%)
     
  • DOW

    33,980.32
    -171.69 (-0.50%)
     
  • BTC-GBP

    19,358.85
    -564.82 (-2.83%)
     
  • CMC Crypto 200

    557.23
    -15.58 (-2.72%)
     
  • ^IXIC

    12,938.12
    -164.43 (-1.25%)
     
  • ^FTAS

    4,146.49
    -19.89 (-0.48%)
     

GSK racks up £1.4bn in COVID sales ahead of consumer health split

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·Finance Reporter, Yahoo Finance UK
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
A GSK scientist studies cancer cells inside white blood cells through a microscope at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019.  REUTERS/Peter Nicholls
GSK reported full-year sales of £34bn. Photo:Peter Nicholls/Reuters

Pharmaceutical giant GlaxoSmithKline (GSK.L) racked up £1.4bn in COVID-related sales as the company remains on track to split its consumer healthcare business by the middle of 2022.

Pre-tax profits were down by more than a fifth last year to £5.4bn, while revenue grew 5% to £34.1bn.

Pharmaceuticals sales up 4% at £17.7bn, with COVID-related sales accounting for £1.4bn in 2021, driven largely by its antibody drug sotrovimab.

The company forecasts a rise in operating profits between 12% and 14% this year as both sales and earnings beat expectations in the fourth quarter.

GSK said it remained on track to de-merge its consumer healthcare business by the middle of 2022, a spin-off that follows the company’s rejection of Unilever’s £50bn offer for the maker of over-the-counter medicines and vitamins late last year.

Read more: Big pharma fined £35m by competition regulator over NHS drug prices

Emma Walmsley, chief executive of GSK, said: “We have ended the year strongly, with another quarter of excellent performance driven by first-class commercial execution, and we enter 2022 with good momentum.

“This is going to be a landmark year for GSK, with a step-change in growth expected and multiple R&D catalysts, including milestones on up to seven key late-stage pipeline assets.

“2022 is also the year when we demerge our world-leading consumer healthcare business.”

A capital markets event later this month will set out the growth ambitions for the demerged consumer healthcare business.

GSK rose 0.5% after it forecast higher profits ahead of its consumer health spin-off. Chart: Yahoo Finance UK
GSK rose 0.5% after it forecast higher profits ahead of its consumer health spin-off. Chart: Yahoo Finance UK

The healthcare giant confirmed three major product approvals over the course of 2021 and currently has 43 medicines and 21 vaccines in its development pipeline.

Read more: COVID puts more than one million workers on universal credit

Sheena Berry, equity analyst at Quilter Cheviot, said: Overall, GSK’s quarterly results and guidance were fine, but nothing to shout about.

“Strengthening the pipeline remains a focus with the data from the RSV vaccine in the first half of this year an important catalyst. A sale of the consumer business would also provide GSK with significant cash to invest in the pipeline.”

The company will pay a dividend of 23p per share for the quarter.

Watch: Unilever all but drops bid for GSK consumer arm

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting